Michael Raghunath

Prof. Dr. Michael Raghunath

Center for Cell Biology & Tissue Engineering, Institute for Chemistry and Biotechnology (ICBT), Zurich University of Applied Sciences (ZHAW), Wädenswil, Switzerland
orcid

Research Focus & Metrics

Academic Career Length

40Years (1987-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 October 2017 in Stem Cells Translational Medicine
Verified
Journal Article
Open access
PDF file
RSRebekah Margaret Samsonraj
Rebekah Margaret Samsonraj
Michael RaghunathMichael Raghunath
Michael Raghunath
VNVictor Nurcombe
Victor Nurcombe
JHJames H. Hui
James H. Hui
Andre J. van WijnenAndre J. van Wijnen
Andre J. van Wijnen
SCSimon M. Cool
Simon M. Cool
Mesenchymal stem cells (MSC) hold great potential for regenerative medicine because of their ability for self-renewal and differentiation into tissue-specific cells such as osteoblasts, chondrocytes, and adipocytes. MSCs orchestrate tissue development, maintenance and repair, and are useful for musculoskeletal regenerative therapies to treat age-related orthopedic degenerative diseases and other clinical conditions. Importantly, MSCs produce secretory factors that play critical roles in tissue repair that support both engraftment and trophic functions (autocrine and paracrine). The development of uniform protocols for both preparation and characterization of MSCs, including standardized functional assays for evaluation of their biological potential, are critical factors contributing to their clinical utility. Quality control and release criteria for MSCs should include cell surface markers, differentiation potential, and other essential cell parameters. For example, cell surface marker profiles (surfactome), bone-forming capacities in ectopic and orthotopic models, as well as cell size and granularity, telomere length, senescence status, trophic factor secretion (secretome), and immunomodulation, should be thoroughly assessed to predict MSC utility for regenerative medicine. We propose that these and other functionalities of MSCs should be characterized prior to use in clinical applications as part of comprehensive and uniform guidelines and release criteria for their clinical-grade production to achieve predictably favorable treatment outcomes for stem cell therapy. Stem Cells Translational Medicine 2017;6:2173–2185

1 May 2008 in Biomaterials
Verified
Journal Article
Open access
Dimitrios ZeugolisDimitrios Zeugolis
Dimitrios Zeugolis
SKShih T. Khew
Shih T. Khew
EYElijah S.Y. Yew
Elijah S.Y. Yew
AEAndrew K. Ekaputra
Andrew K. Ekaputra
YTYen Wah Tong
Yen Wah Tong
Michael RaghunathMichael Raghunath
Michael Raghunath
Scaffolds manufactured from biological materials promise better clinical functionality, providing that characteristic features are preserved. Collagen, a prominent biopolymer, is used extensively for tissue engineering applications, because its signature biological and physico-chemical properties are retained in in vitro preparations. We show here for the first time that the very properties that have established collagen as the leading natural biomaterial are lost when it is electro-spun into nano-fibres out of fluoroalcohols such as 1,1,1,3,3,3-hexafluoro-2-propanol or 2,2,2-trifluoroethanol. We further identify the use of fluoroalcohols as the major culprit in the process. The resultant nano-scaffolds lack the unique ultra-structural axial periodicity that confirms quarter-staggered supramolecular assemblies and the capacity to generate second harmonic signals, representing the typical crystalline triple-helical structure. They were also characterised by low denaturation temperatures, similar to those obtained from gelatin preparations (p>0.05). Likewise, circular dichroism spectra revealed extensive denaturation of the electro-spun collagen. Using pepsin digestion in combination with quantitative SDS-PAGE, we corroborate great losses of up to 99% of triple-helical collagen. In conclusion, electro-spinning of collagen out of fluoroalcohols effectively denatures this biopolymer, and thus appears to defeat its purpose, namely to create biomimetic scaffolds emulating the collagen structure and function of the extracellular matrix.

21 May 2015 in Stem Cells
Verified
Journal Article
Open access
PDF file
RSRebekah Margaret Samsonraj
Rebekah Margaret Samsonraj
BRBina Rai
Bina Rai
PSPadmapriya Sathiyanathan
Padmapriya Sathiyanathan
KPKia Joo Puan
Kia Joo Puan
OROlaf Rötzschke
Olaf Rötzschke
SCSimon M. Cool
Simon M. Cool
This study sought to identify critical determinants of mesenchymal stem cell (MSC) potency using in vitro and in vivo attributes of cells isolated from the bone marrow of age- and sex-matched donors. Adherence to plastic was not indicative of potency, yet capacity for long-term expansion in vitro varied considerably between donors, allowing the grouping of MSCs from the donors into either those with high-growth capacity or low-growth capacity. Using this grouping strategy, high-growth capacity MSCs were smaller in size, had greater colony-forming efficiency, and had longer telomeres. Cell-surface biomarker analysis revealed that the International Society for Cellular Therapy (ISCT) criteria did not distinguish between high-growth capacity and low-growth capacity MSCs, whereas STRO-1 and platelet-derived growth factor receptor alpha were preferentially expressed on high-growth capacity MSCs. These cells also had the highest mean expression of the mRNA transcripts TWIST-1 and DERMO-1. Irrespective of these differences, both groups of donor MSCs produced similar levels of key growth factors and cytokines involved in tissue regeneration and were capable of multilineage differentiation. However, high-growth capacity MSCs produced approximately double the volume of mineralized tissue compared to low-growth capacity MSCs when assessed for ectopic bone-forming ability. The additional phenotypic criteria presented in this study when combined with the existing ISCT minimum criteria and working proposal will permit an improved assessment of MSC potency and provide a basis for establishing the quality of MSCs prior to their therapeutic application. Stem Cells 2015;33:1878–1891

1 June 2019 in Advanced Drug Delivery Reviews
Verified
Journal Article
Closed access
JCJoão Q. Coentro
João Q. Coentro
EPEugenia Pugliese
Eugenia Pugliese
GHGeoffrey Hanley
Geoffrey Hanley
Michael RaghunathMichael Raghunath
Michael Raghunath
Dimitrios ZeugolisDimitrios Zeugolis
Dimitrios Zeugolis

1 April 2011 in Advanced Drug Delivery Reviews
Verified
Journal Article
Closed access
CCClarice Chen
Clarice Chen
FLFelicia Loe
Felicia Loe
Ana BlockiAna Blocki
Ana Blocki
YPYanxian Peng
Yanxian Peng
Michael RaghunathMichael Raghunath
Michael Raghunath

20 October 2009 in British Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
CCCzc Chen
Czc Chen
YPYx Peng
Yx Peng
ZWZb Wang
Zb Wang
PFPv Fish
Pv Fish
JKJl Kaar
Jl Kaar
Michael RaghunathMichael Raghunath
Michael Raghunath
Background and purpose:  Fibrosis, a pathological accumulation of collagen in tissues, represents a major global disease burden. Effective characterization of potential antifibrotic drugs has been constrained by poor formation of the extracellular matrix in vitro, due to tardy procollagen processing by collagen C‐proteinase/BMP‐1, and difficulties in relating this matrix to cell numbers in experimental samples.Experimental approach:  The Scar‐in‐a‐Jar model provided, in vitro, the complete biosynthetic cascade of collagen matrix formation including complete conversion of procollagen by C‐proteinase/BMP‐1, its subsequent extracellular deposition and lysyl oxidase‐mediated cross‐linking, achieved by applying the biophysical principle of macromolecular ‘crowding’. Collagen matrix deposition, velocity and morphology can be controlled using negatively charged ‘crowders’ in a rapid (2 days) mode or a mixture of neutral ‘crowders’ in an accelerated (6 days) mode. Combined with quantitative optical bioimaging, this novel system allows for in situ assessment of the area of deposited collagen(s) per cell.Key results:  Optical evaluation of known and novel antifibrotic compounds effective at the epigenetic, post‐transcriptional/translational/secretional level correlated excellently with corresponding biochemical analyses. Focusing on quantitation of deposited collagen, the Scar‐in‐a‐Jar was most effective in assessing novel inhibitors that may have multiple targets, such as microRNA29c, found to be a promising antifibrotic agent.Conclusions and implications:  This novel screening system supersedes current in vitro fibroplasia models, as a fast, quantitative and non‐destructive technique. This method distinguishes a reduction in collagen I deposition, excluding collagen cross‐linking, and allows full evaluation of inhibitors of C‐proteinase/BMP‐1 and other matrix metalloproteinases.